Digital Health Unit

Market analysis and business model for novel test procedure for the development of fibrosis drugs

Causal treatment of organ fibrosis – a pathological proliferation of connective tissue, for instance in the lungs, heart or liver – has been almost impossible up until now. In the FibroPaths® project, four Fraunhofer Institutes: Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Fraunhofer Institute for Digital Medicine MEVIS, Fraunhofer Institute for Material and Beam Technology IWS and Fraunhofer IMW have joined forces to facilitate preclinical testing of antifibrotic drugs and consequently the development of fibrosis medication by developing a biochip.